Spain Lung Cancer Therapeutics Market Report 2022 to 2030

Spain Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Spain Lung Cancer Therapeutics Market will reach a value of $996 Mn from $575 Mn in 2022, growing at a CAGR of 7.1% during 2022-2030. The Lung Cancer Therapeutics Market in Spain is dominated by a few domestic pharmaceutical companies such as Grifols, PharmaMar, and Almirall. The Lung Cancer Therapeutics Market in Spain is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Spain lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10ESPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Dr. Vishwa Modhia

Buy Now

Spain Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Spain Lung Cancer Therapeutics market will reach a value of $996 Mn from $575 Mn in 2022, growing at a CAGR of 7.1% during 2022-2030.

Spain is a high-income developed country located in Southwestern Europe. The coastlines include the Bay of Biscay, the Mediterranean Sea, and the Northern Atlantic Ocean. After colorectal, prostate, and breast cancers, lung cancer is the fourth most prevalent cancer diagnosed in both sexes in Spain, with a 5-year survival rate of 12.7 % in men and 17.6 % in women reported from 2008 to 2013. Almost one-third of all new lung cancer cases identified in Spain each year is resected, and induction therapy is frequently recommended for patients with locally advanced lung cancer. Standard cytotoxic immunotherapy and targeted treatments are widely available across the country in all centres.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Spain reached 22,131 or 6.70% of total deaths. The age-adjusted Death Rate is 22.84 per 100,000 population ranks Spain 36^th in the world. Spain's government spends 10.7 % of its GDP on healthcare.

Spain Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

In 2019, there were 29,053 cases of lung cancer in Spain (22,083 in men and 7420 in women). While the incidence of lung cancer continues to rise (29,638 expected new cases in 2020), this is primarily visible among women, with an estimated 5.0 % increase in 2020; men, on the other hand, are on the decline (1.1 %). In Spain, 250 board-certified thoracic surgeons (0.55 per 100,000 people) conduct lung cancer surgery in 77 hospitals. This physician population is quite youthful (65 % are under the age of 50), with one-third being female. Financial aid from European institutions to Spain has continuously increased. Private investment has expanded the volume and availability of technical equipment in Spanish radiation oncology departments during the last decade. Furthermore, the industrial industry in Spain has recently demonstrated its ability to reinvent itself. These aspects could boost Spain's Lung Cancer Therapeutics market.

Market Restraints

Minimizing smoking incidence (particularly among adolescents and women), enhancing access to genetic profiling, and reducing treatment disparities are all critical and serious future issues. Spain is particularly exposed to pandemic-risk industries. It has a distorted labour market and high structural unemployment. These factors may deter new entrants into the Spain Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Grifols: Grifols is a Spanish multinational pharmaceutical and chemical company that produces several drugs for the treatment of cancer, including lung cancer
PharmaMar: PharmaMar is a Spanish biopharmaceutical company that produces several drugs for the treatment of lung cancer, including Zepsyre and Aplidin
Almirall: Almirall is a Spanish pharmaceutical company that produces several drugs for the treatment of cancer, including lung cancer
Bioiberica: Bioiberica is a Spanish biotechnology company that is focused on the development of innovative therapies for the treatment of cancer, including lung cancer

Recent Notable Updates

January 2023: The Federal Commission for the Protection against Sanitary Risks of Mexico (COFEPRIS) has granted full approval for the commercialization of Zepzelca to the Spanish company PharmaMar's licencing partner, Adium Pharma, for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) who have disease progression on or after platinum-based chemotherapy. This new approval is based on the monotherapy clinical results from the open-label, multi-centre, single-arm clinical trial in 105 adult patients with recurrent SCLC that the Food and Drug Administration (FDA) used to grant lurbinectedin expedited approval in the US.

Healthcare Policies and Reimbursement Scenarios

Lung cancer therapeutics in Spain are controlled and reimbursed by several organizations, including the Spanish Agency of Medicines and Medical Devices (AEMPS), the Spanish Ministry of Health, and the Spanish healthcare system. The AEMPS is responsible for the regulation and approval of lung cancer therapeutics in Spain.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.